Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Available 1

Sponsor Class

OTHER 4INDUSTRY 2NETWORK 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 4Uveal Melanoma 2Select Advanced Solid Tumors 1Nevus, Blue 1Diabetes Mellitus, Insulin-Dependent, 12 1Advanced or Metastatic Solid Tumors 1

Interventions

pembrolizumab 7Ipilimumab 7Nivolumab 5Melphalan 5Dacarbazine 3tebentafusp 2sotrastaurin 2binimetinib 2Pemetrexed 2Crizotinib 2ADI PEG20 2utomilumab 1trametinib 1tocilizumab 1siremadlin 1ruxolitinib 1relatlimab 1obinutuzumab 1fludarabine phosphate 1fludarabine 1cemiplimab 1avelumab 1Watchful Waiting 1Toll-Like Receptor 1 1Standard of Care 1Solutions 1Rose Bengal 1Protein Kinase C 1Polyethylene Glycols 1Opdualag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Uveal Melanoma × tebentafusp × Clear all
NCT02570308 2023-03-21

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

Immunocore Ltd

Phase 1/2 Completed
146 enrolled 26 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT04960891 2022-01-21

Non Applicable

Immunocore Ltd

Available
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡